Krka Does Not Expect Short-Term Damage Due to Changes in Act on Medicinal Products

Novo Mesto, 22 January - Revenues of the Slovene pharmaceutical company Krka topped SIT 72 billion (EUR 324 million) in 2001, exceeding those of 2000 by 17 percent. Net profits, too, recorded a substantial increase year-on-year, Krka chief executive Milos Kovacic told the press on Tuesday, however he refused to disclose the exact figure before the management board convenes in February.